Výsledky vyhledávání

Akademický článek

An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.

Autor: Piena MA; MMA, Evidence & Access, OPEN Health, Rotterdam, Netherlands., Kroep S; MMA, Evidence & Access, OPEN Health, Rotterdam, Netherlands., Simons C; MMA, Evidence & Access, OPEN Health, York, UK., Fenwick E; MMA, Evidence & Access, OPEN Health, Oxford, UK., Harty GT; The Healthcare Business of Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany. Gerard.Harty@merckgroup.com., Wong SL; EMD Serono, Billerica, MA, USA., van Hout BA; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.

Publikováno v: Advances in therapy [Adv Ther] 2022 Feb; Vol. 39 (2), pp. 892-908. Date of Electronic Publication: 2021 Nov 18.

Zobrazit plný text záznamu

Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.

Publikováno v: Advances in therapy [Adv Ther] 2022 Feb; Vol. 39 (2), pp. 909.

Zobrazit plný text záznamu

Akademický článek

Mapping EQ-5D-3L to EQ-5D-5L.

Autor: van Hout BA; University of Sheffield. Electronic address: b.a.vanhout@sheffield.ac.uk., Shaw JW; Bristol Meyers Squibb, Princeton Pike, Lawrenceville, NJ.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2021 Sep; Vol. 24 (9), pp. 1285-1293. Date of Electronic Publication: 2021 May 18.

Zobrazit plný text záznamu

Akademický článek

Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.

Autor: Sarker J; Department of Pharmacy Systems, Outcomes, and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA. jsarke3@uic.edu., Tice JA; Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA., Rind DM; Institute for Clinical and Economic Review, Boston, MA, USA., Walton SM; Department of Pharmacy Systems, Outcomes, and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA.

Publikováno v: Applied health economics and health policy [Appl Health Econ Health Policy] 2024 Dec 02. Date of Electronic Publication: 2024 Dec 02.

Zobrazit plný text záznamu

Cost-effectiveness of additional blood screening tests in the Netherlands

Autor: Borkent-Raven, BA, Janssen, MP, van der Poel, CL, Bonsel, Gouke, van Hout, BA (Ben)

Publikováno v: Transfusion, 52(3), 478-488. Wiley-Blackwell Publishing Ltd

BACKGROUND: During the past decade, blood screening tests such as triplex nucleic acid amplification testing (NAT) and human T-cell lymphotropic virus type I or I (HTLV-I/II) antibody testing were added to existing serologic testing for hepatitis B v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::4a0f221f5af4ba1aed9d08cdb9679cd1
https://pure.eur.nl/en/publications/c1418e95-4a36-4500-8b08-a0e5d0800cde

Zobrazit plný text záznamu

The PROTON study: profiles of blood product transfusion recipients in the Netherlands

Autor: Borkent-Raven, BA, Janssen, MP, van der Poel, CL, Schaasberg, WP, Bonsel, Gouke, van Hout, BA (Ben)

Publikováno v: Vox Sanguinis, 99(1), 54-64. Wiley-Blackwell Publishing Ltd

Background Transfusion recipient data are needed for correct estimation of cost-effectiveness in terms of recipient outcomes after transfusion. Also, such data are essential for monitoring blood use, estimation of future blood use and benchmarking. S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::d9b1fa8afe02646b08dbd87174581dbb
https://pure.eur.nl/en/publications/31c8d40f-7299-47cf-89ee-e1a48d509a07

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání